Pacific Biosciences of California Inc (PACB)

Industry Medical Devices
This stock can be held in an Investment ISA and an Investment Account
Sell

$1.07

Buy

$1.09

arrow-down$-0.04 (-3.64%)

Pacific Biosciences of California Inc is a biotechnology company. It is engaged in design, development, and manufacture of sequencing system to help scientists resolve genetically complex problems.
Prices updated at 16 May 2025, 00:59 EDT
| Prices minimum 15 mins delay
|
Prices in USD
NASDAQ
arrow-down-0.18%
NASDAQ
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
Our Investment Fees and Charges.
Sector
Healthcare
Industry
Medical Devices
Chairman
Dr. John F. Milligan, PhD
CEO
Mr. Christian O. Henry
Most recent earnings
31 Dec 2024
Fiscal year end
31 Dec 2024
Employees
575
Head office
1305 O’Brien Drive
Menlo Park
United States
94025
mobile
+1 650 521-8000
letter
ir@pacificbiosciences.com
computer
Company website

Key personnel

Owner nameSalaryBonusAll other compensationTotal compensationRestricted stock award
Mr. Christian O. Henry
Director, Chief Executive Officer, President and Chief Commercial Officer
0.73m--9.18m-
Mr. Christopher M. Smith
Director
-----
Mr. JIm R. Gibson
Chief Financial Officer
-----
Ms. Kathy P. Ordonez
Independent Director
0.06m--0.13m-
Dr. Lucy Shapiro, PhD
Independent Director
0.06m--0.13m-
Mr. Marshall L. Mohr
Independent Director
0.06m--0.13m-
Mr. Randall S. Livingston
Independent Director
0.07m--0.14m-
Mr. William W. Ericson
Independent Director
0.06m--0.13m-
Dr. John F. Milligan, PhD
Chairman of the Board
0.10m--0.17m-
Mr. Mark Van Oene
Chief Operating Officer
0.60m--4.81m-
Dr. Hannah A. Valantine, M.D.
Independent Director
0.05m--0.13m-
Ms. Michele Farmer
Vice President and Chief Accounting Officer
-----

Top 5 shareholders

Owner nameNo. of sharesShare as % of port.Last changePortfolio % changeDate of portfolio% Total assets
ARK Investment Management LLC36,478,4410.430854340791.20429130 Apr 202512.16
BlackRock Inc23,455,2520.00058-1139521-4.63318430 Apr 20257.82
Madrone Advisors LLC23,391,9158.15744--30 Apr 20257.80
ARK Disruptive Innovation Full Composite21,745,1520.510995860682.76981730 Apr 20257.25
ARK Innovation ETF21,400,8250.46657-177721-0.823630 Apr 20257.13

Director dealings

DateActionNamePriceValueNo. of sharesHolding (%)Additional info
30 Sep 2024-Ms. Susan G. Kim1.7234,065695,654--
16 Sep 2024-Mr. Christian O. Henry1.75172,6922,497,763--
19 Aug 2024-Mr. Jeff Eidel1.5942,602869,730--
16 Aug 2024-Mr. Oene Mark Van1.6663,1741,630,815--
18 Jun 2024-Mr. David W. Meline--24,134--
18 Jun 2024-Mr. David W. Meline--57,116--
18 Jun 2024-Ms. Kathy P. Ordonez--403,037--
18 Jun 2024-Ms. Kathy P. Ordonez--32,179--
18 Jun 2024-Dr. Lucy Shapiro--22,821--
18 Jun 2024-Dr. Lucy Shapiro--32,179--
18 Jun 2024-Mr. Marshall L. Mohr--32,179--
18 Jun 2024-Mr. Marshall L. Mohr--132,821--
18 Jun 2024-Mr. Randall S. Livingston--32,179--
18 Jun 2024-Mr. Randall S. Livingston--22,821--
18 Jun 2024-Mr. William W. Ericson--41,616--
18 Jun 2024-Mr. William W. Ericson--32,179--
18 Jun 2024-Dr. John F. Milligan, PhD--32,179--
18 Jun 2024-Dr. John F. Milligan, PhD--132,821--
18 Jun 2024-Dr. Hannah A. Valantine, M.D.--32,179--
18 Jun 2024-Dr. Hannah A. Valantine, M.D.--22,821--
Please note that past performance is not a reliable indicator of future returns.


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.